Patents by Inventor Tim Bowden
Tim Bowden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180221495Abstract: A method for treating or preventing the symptoms associated with hang over in an individual suffering from or being at risk for such conditions. The method includes the steps of: i) providing the composition of the invention containing AP, and ii) contacting AP with the mediator a) within the individual, or b) separate from the individual.Type: ApplicationFiled: April 3, 2018Publication date: August 9, 2018Inventors: Tim BOWDEN, Kristoffer BERGMAN, Thomas ENGSTRAND, Lennart SODERBERG
-
Patent number: 9962451Abstract: A composition for treating or preventing inflammatory-related conditions includes as an active principle a carrier which exhibits a plurality of a scavenger structure capable of mitigating the activity of a mediator of inflammatory-related conditions. The scavenger structure includes a nucleophilic center complying with the formula X1(—R?—)(—R?)mHn where: a) X1 is a single-bonded heteroatom selected amongst N, O and S and exhibits a free electron pair; b) m is 0 or 1 and n is 1 or 2; c) —R?— is a bivalent organic group providing attachment to the carrier via one of its free valences and to X1 at the other free valence; and d) R?— is a monovalent organic group attached to the X1 via its free valence. A method for treating or preventing inflammatory-related conditions in an individual suffering from such conditions includes: providing the composition; and contacting the mediator within or separate from the individual.Type: GrantFiled: February 25, 2016Date of Patent: May 8, 2018Assignee: PVAC MEDICAL TECHNOLOGIES LTD.Inventors: Tim Bowden, Kristoffer Bergman, Thomas Engstrand, Lennart Soderberg
-
Patent number: 9585987Abstract: A composition, which upon activation, spontaneously forms a cross-linked hydrogel in aqueous liquid, includes: a) a formulation containing a hyluronan (HA-formulation) which includes a hyaluronan backbone (HA backbone) and a plurality of a reactive substituent group (reactive HA substituent) which i) is directly attached to the HA backbone, and ii) exhibits the reactive HA-group, and b) a formulation of a homo-multifunctional cross-linking reagent (CLR-formulation) exhibiting a plurality of a reactive group (reactive CLR-group). The two reactive groups are selected as a pair of counterparts that mutually and selectively react with each other to form a linkage structure. The hydrogel contains a cross-linking structure which a) is attached to the hyaluronan via two or more of the linkage structure and is defined by the reagent. The cross-linking structure exhibits a plurality of hydroxyl groups. The composition can be used in vivo or ex vivo as a support matrix.Type: GrantFiled: February 13, 2009Date of Patent: March 7, 2017Assignee: PVAC MEDICAL TECHNOLOGIES LTDInventors: Kristoffer Bergman, Tim Bowden, Thomas Engstrand, Jons Hilborn, Dmitri Ossipov
-
Publication number: 20160175451Abstract: A composition for treating or preventing inflammatory-related conditions includes as an active principle a carrier which exhibits a plurality of a scavenger structure capable of mitigating the activity of a mediator of inflammatory-related conditions. The scavenger structure includes a nucleophilic centre complying with the formula X1(—R?—)(—R?)mHn where: a) X1 is a single-bonded heteroatom selected amongst N, O and S and exhibits a free electron pair; b) m is 0 or 1 and n is 1 or 2; c) -R?- is a bivalent organic group providing attachment to the carrier via one of its free valences and to X1 at the other free valence; and d) R?- is a monovalent organic group attached to the X1 via its free valence. A method for treating or preventing inflammatory-related conditions in an individual suffering from such conditions includes: providing the composition; and contacting the mediator within or separate from the individual.Type: ApplicationFiled: February 25, 2016Publication date: June 23, 2016Inventors: Tim BOWDEN, Kristoffer BERGMAN, Thomas ENGSTRAND, Lennart SODERBERG
-
Patent number: 9302013Abstract: A composition for treating or preventing inflammatory-related conditions includes as an active principle a carrier which exhibits a plurality of a scavenger structure capable of mitigating the activity of a mediator of inflammatory-related conditions. The scavenger structure includes a nucleophilic center complying with the formula X1(—R?—)(—R?)mHn where: a) X1 is a single-bonded heteroatom selected amongst N, O and S and exhibits a free electron pair; b) m is 0 or 1 and n is 1 or 2; c) —R?— is a bivalent organic group providing attachment to the carrier via one of its free valences and to X1 at the other free valence; and d) R?— is a monovalent organic group attached to the X1 via its free valence. A method for treating or preventing inflammatory-related conditions in an individual suffering from such conditions includes: providing the composition; and contacting the mediator within or separate from the individual.Type: GrantFiled: January 25, 2012Date of Patent: April 5, 2016Assignee: TERMIRA ABInventors: Tim Bowden, Kristoffer Bergman, Thomas Engstrand, Lennart Soderberg
-
Publication number: 20130302268Abstract: A composition for treating or preventing inflammatory-related conditions includes as an active principle a carrier which exhibits a plurality of a scavenger structure capable of mitigating the activity of a mediator of inflammatory-related conditions. The scavenger structure includes a nucleophilic centre complying with the formula X1(—R?—)(—R?)mHnwhere: a) X1 is a single-bonded heteroatom selected amongst N, O and S and exhibits a free electron pair; b) m is 0 or 1 and n is 1 or 2; c) —R?— is a bivalent organic group providing attachment to the carrier via one of its free valences and to X1 at the other free valence; and d) R?— is a monovalent organic group attached to the X1 via its free valence. A method for treating or preventing inflammatory-related conditions in an individual suffering from such conditions includes: providing the composition; and contacting the mediator within or separate from the individual.Type: ApplicationFiled: January 25, 2012Publication date: November 14, 2013Applicant: IPR-Systems Sweden AB, C/O Tim BowdenInventors: Tim Bowden, Kristoffer Bergman, Thomas Strand, Lennart Soderberg
-
Publication number: 20110008444Abstract: A composition, which upon activation, spontaneously forms a cross-linked hydrogel in aqueous liquid, includes: a) a formulation containing a hyluronan (HA-formulation) which includes a hyaluronan backbone (HA backbone) and a plurality of a reactive substituent group (reactive HA substituent) which i) is directly attached to the HA backbone, and ii) exhibits the reactive HA-group, and b) a formulation of a homo-multifunctional cross-linking reagent (CLR-formulation) exhibiting a plurality of a reactive group (reactive CLR-group). The two reactive groups are selected as a pair of counterparts that mutually and selectively react with each other to form a linkage structure. The hydrogel contains a cross-linking structure which a) is attached to the hyaluronan via two or more of the linkage structure and is defined by the reagent. The cross-linking structure exhibits a plurality of hydroxyl groups. The composition can be used in vivo or ex vivo as a support matrix.Type: ApplicationFiled: February 13, 2009Publication date: January 13, 2011Applicant: IPR-SYSTEMS SWEDEN ABInventors: Kristoffer Bergman, Tim Bowden, Thomas Engstrand, Jons Hilborn, Dmitri Ossipov
-
Publication number: 20060147490Abstract: The present invention provides a biodegradable, biocompatible polymer that is capable of forming particles (micelles), vesicles, surfaces and membranes, and other structures in which a biologically active agent, e.g. a drug, can be incorporated in such a way that its release to the host can be controlled to a high degree of accuracy, or in where surfaces of the formed polymers can be used to increase the hemeo compatibility of biomaterials. The present invention provides polymer compounds comprising at least one biodegradable polyester having a terminal functional group based on hydrophilic moieties from a phospholipid.Type: ApplicationFiled: September 5, 2003Publication date: July 6, 2006Inventors: Tim Bowden, Fredrik Nederberg, Jon Hillborn